Maquet Medical Systems USA Announces Exclusive US Distribution Agreement with ClearFlow for PleuraFlow® Active Clearance Technology® System


WAYNE, N.J., Jan. 23, 2015 /PRNewswire/ -- Maquet Medical Systems USA announced today an exclusive US distribution agreement with ClearFlow, Inc. for its innovative PleuraFlow® Active Clearance Technology® (ACT™) System. The PleuraFlow System enables caregivers to actively keep chest drainage tubes clear of clot in the early hours after heart surgery. Maquet's sales representatives in the United States will begin selling PleuraFlow ACT during the first quarter of 2015. PleuraFlow ACT received 510(k) regulatory clearance from the U.S. Food and Drug Administration in December 2010. In October 2014, ClearFlow announced positive results from the Prevention of Retained Blood Outcomes Using Active Clearance Technology trial, (PRO-ACT), a clinical study evaluating the use of PleuraFlow® … [Read more...]

ClearFlow announces positive clinical trial results for the reduction of hospital complications after heart surgery

Washington, DC.—October 10, 2014—ClearFlow Inc., a medical device company based in Anaheim, CA, today announced positive results from the Prevention of Retained Blood Outcomes Using Active Clearance Technology trial, (PRO-ACT), a clinical study evaluating the use of PleuraFlow® Active Clearance Technology™ System to prevent retained blood complications. The PleuraFlow System enables caregivers to actively keep chest drainage tubes clear of clot in the early hours after heart surgery.   The PRO-ACT studied the efficacy of a protocol for actively clearing chest tubes of clotted blood to prevent retained blood complications. “Chest tube clogging is known to occur in over one-third of heart surgery patients in the early hours after heart surgery, and nearly one in … [Read more...]

Mark your calendar!

On Friday, October 10th investigators will report clinical trial results from the Prevention of Retained Blood Outcomes with Active Clearance Technology (PROACT) assessing the use of PleuraFlow to reduce Retained Blood Complications after Cardiac Surgery at FACTS-Care CVT 2014 in Washington, D.C. This is one of the largest studies to assess outcomes with Active Clearance Technology to reduce complications after heart surgery.   … [Read more...]

Results of PleuraFlow Clinical Studies to be Released At CVT

Anaheim, CA., Oct. 1, 2014 -- ClearFlow, Inc., a medical device company based in Anaheim, CA, announced that results from the PRO-ACT trial, (Prevention of Retained Blood Outcomes Using Active Clearance Technology), a clinical study evaluating the use of PleuraFlow® Active Clearance Technology™ System to prevent Retained Blood Complications (RBC) will be presented at the upcoming Cardiovascular-Thoracic (CVT) Critical Care meeting in Washington, D.C. next week. CVT is the scientific annual meeting of FACTS-Care (Foundation for the Advancement of CardioThoracic Surgical Care).  The foundation promotes coordination of all members of the cardiovascular surgery team to advance knowledge and expertise in caring for the critically ill cardiothoracic surgery patients. Specialists … [Read more...]

Surgeons Share Methods to Reduce Retained Blood Complications after Heart Surgery


Toronto, Canada—May 5, 2014—Distinguished physicians from leading cardiac surgery centers gathered at an Educational Symposium to share their experiences with a new-generation blood evacuation system for use following cardiothoracic surgical procedures. ClearFlow, Inc. hosted the Symposium at the recent American Association of Thoracic Surgeon’s meeting in Toronto, Canada, where their award-winning technology was on exhibit for over 2,400 cardiac surgeons and healthcare professionals. Marc Gillinov, MD, a surgeon from the Cleveland Clinic discussed the incidence and consequences of the complications that can result from the incomplete evacuation of blood from a patient’s chest after cardiac surgery. Louis Perrault, MD, from Montreal Heart Institute described the lack of best … [Read more...]

ClearFlow Appoints Senior Sales Executive to N.America Leadership Position


Anaheim, California. ClearFlow Inc., a venture-funded designer and manufacturer of PleuraFlow® Active Clearance Technology™, a new generation blood evacuation system for use following cardiothoracic surgical procedures is pleased to announce that Mr. Michael Cox has joined the Company as Vice President of Sales, North America. Michael has progressed through successful sales and marketing leadership roles in major cardiovascular device firms including Edwards Lifesciences and AtriCure, most recently leaving Austin, Texas based heart-valve manufacturer On-XLife Technologies, Inc. to join ClearFlow. “We are thrilled to strengthen our senior management team with a sales executive of Michael’s caliber and proficiency” said ClearFlow President & CEO, Mr. Paul Molloy. … [Read more...]

Clear Catheter Systems Changes Name to ClearFlow


We are excited to announce that Clear Catheter Systems, Inc. is now ClearFlow, Inc.  Our mission is to develop the best devices to proactively drain blood and fluids after surgery. We believe that avoiding the complications that accrue to retained blood and fluids leads to reduced morbidity and mortality, less pain and discomfort for the patient, and lower total cost of care in a cost-conscious healthcare environment. We are focused on helping clinicians eliminate the acute, sub-acute and chronic postoperative complications of current high failure-rate wound drainage tubes by offering the only CE marked and 510(k) cleared drainage system with Active Clearance Technology™.  ClearFlow’s patented PleuraFlow® ACT System reliably maintains chest tube patency in the critical … [Read more...]

Excitement for PleuraFlow Grows Across Canada – PleuraFlow Takes Center Stage at Three Successful Meetings in Canada


Interest in Clear Catheter System Inc. continues to spike after three strong meetings in Canada aimed at educating cardiac surgeons about PleuraFlow® Active Clearance Technology®, its positive impact in reducing complications related to Retained Blood and Fluids, and improving patient outcomes as well as reducing hospital costs. Led by Dr. Louis P. Perrault, Chief of Service for the Department of Surgery at Montreal Heart Institute and Professor of Surgery and Pharmacology at the Université de Montréal, the novel PleuraFlow medical device took center stage at three meetings. Dr. Perrault explained the unique technology and its benefits to the guests gathered from area hospitals across Montreal and Toronto while Clear Catheter Systems President and Chief Executive Officer, Paul … [Read more...]

Clear Catheter Systems Wins Prestigious International Innovation Award


2013 “Innovations in Cardiovascular Interventions” Top Prize goes to Medical Device Start-up for PleuraFlow Clear Catheter Systems, Inc., announced today it has won the 2013 Innovations in Cardiovascular Interventions (ICI) Best Start-Up Innovation Award for its medical device, PleuraFlow®, a novel system that optimally evacuates blood and fluid after surgery to speed recovery and improve patient outcomes in the ICU during the initial critical hours after heart surgery. The honor was awarded to Dr. Edward Boyle, a surgeon, Chairman of Clear Catheter Systems and an inventor of the PleuraFlow® device, which prevents chest tube clogging to minimize the problem of Retained Blood Complications after heart surgery. Clear Catheter Systems plans to expand use of its PleuraFlow® Active … [Read more...]

PleuraFlow Inventor Speaks at 31st Annual Cardiovascular Surgical Symposium

Zürs, Austria – Edward M. Boyle, MD, the inventor of PleuraFlow and founder and CEO of Clear Catheter Systems spoke at the 31st annual Cardiovascular Surgical Symposium in Zürs, Austria, on March 8th. This is a premier gathering of many of Europe's top heart surgeons in an interactive setting to promote exchange of ideas and updates on the use and development of new technologies.  In his presentation, "New Approaches to Prevent Retained Blood Complex after Heart Surgery," Dr. Boyle discussed the most up-to-date research on Retained Blood Complex (RBC), and the impact of PleuraFlow Active Clearance Technology  and PROACT programs. “It was evident that RBC plays a significant role in cardiac surgery care, as there was considerable interest in the clinical aspects of preventing … [Read more...]

ClearFlow's PleuraFlow® Active Clearance Technology and many of its features are protected by a comprehensive family of both US and foreign patents and patent applications in major markets throughout the world, including Canada, Australia and the European Community. In the United States, PleuraFlow® products are protected by US Patent Nos. 7,854,728, 7,951,243, 8,246,752, 8,048,233, 8,388,759 and 8,702,662. The PleuraFlow® product is the first device of its kind to effectively and reproducibly clear obstructing material from chest tubes without compromising the sterile field, and thus patient recovery. It is the only FDA 510(k) cleared device of its kind for this indication. ClearFlow's patent portfolio has been tailored not only to protect this product, but also to provide protection around this new market segment thus presenting a barrier to entry for competing products.